تصفح College of Medicine حسب الموضوع "vandetanib"
السجلات المعروضة 1 -- 1 من 1
-
Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
( Taylor and Francis Ltd , 2020 , Article)Objectives: Recent studies have shown an increase risk of cardiovascular and hematological adverse events associated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs). The authors hypothesize ...